ClinicalTrials.gg
RecruitingNCT05090891ProgressUpdated Oct 22, 2026

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

A Phase 2 interventional study of INCB000928 and Placebo in Fibrodysplasia Ossificans Progressiva (FOP), sponsored by Incyte Corporation. Recruiting at 24 sites in 17 countries. Open to participants aged 2 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
2 Years to 99 Years
Sex
All
01

Study summary

This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).

02

Conditions studied

  • Fibrodysplasia Ossificans Progressiva (FOP)

Keywords

  • fibrodysplasia ossificans progressiva (FOP)
  • heterotopic ossification
03

In context

Myositis Ossificans

24 studies on the registry are indexed under Myositis Ossificans; 5 are open to participants now.

This study's planned enrollment of 98 is above the median of 48 across 16 interventional studies indexed under Myositis Ossificans.

Browse Myositis Ossificans studies →

Lead sponsor

Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.

Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female and male participants:

    • Cohort 1: ≥ 12 years of age.
    • Cohort 2: 6 to \< 12 years of age.
    • Cohort 3: 2 to \< 12 years of age (after eDMC review of safety data from Cohort 2).
  • Clinical diagnosis of FOP.
  • Willingness to avoid pregnancy or fathering children based on the criteria below.
  • Willing and able to undergo low-dose WBCT (excluding the head) imaging without requiring intubation.
  • Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast-feeding.
  • CAJIS score ≥ 24.
  • FOP disease severity that in the investigator's opinion precludes participation.
  • Any medical condition other than FOP that would, in the investigator's judgment, interfere with full participation in the study, pose a significant risk to the participant, or interfere with interpretation of study data.
  • Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment.
  • , , or infection. Note:
  • Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Participants (≥ 12 years of age) will receive INCB000928 or placebo as defined in the protocol for 24 weeks (double-blind period). Participants who complete the double-blind period will continue into open-label extension period for an additional 292 weeks.

    Drug: INCB000928 · Drug: Placebo

  • Experimental
    Cohort 2

    Participants (6 to \< 12 years of age) will receive INCB000928 or placebo as defined in the protocol for 24 weeks (double-blind period). Participants who complete the double-blind period will continue into open-label extension period for an additional 292 weeks.

    Drug: INCB000928 · Drug: Placebo

  • Experimental
    Cohort 3

    Participants (2 to \< 12 years of age) will receive INCB000928 or placebo as defined in the protocol for 24 weeks (double-blind period). Participants who complete the double-blind period will continue into open-label extension period for an additional 292 weeks.

    Drug: INCB000928 · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Double Blind Period: Occurrence of new heterotopic ossification (HO) lesions from baseline

    HO will be assessed by low dose whole-body computed tomography (WBCT) (excluding the head) compared to baseline during the double-blind period.

    Time frame: Week 24

Secondary outcomes

  1. Double Blind Period: Number of new HO lesions from baseline

    HO will be assessed by low dose whole-body computed tomography (WBCT) (excluding the head) compared to baseline during the double-blind period.

    Time frame: Week 24

  2. Double Blind Period: Total volume of new HO lesions from baseline

    HO will be assessed by low dose whole-body computed tomography (WBCT) (excluding the head) compared to baseline during the double-blind period.

    Time frame: Week 24

  3. Double Blind Period: Change in the total volume of all HO lesions from baseline

    HO will be assessed by low dose whole-body computed tomography (WBCT) (excluding the head) compared to baseline during the double-blind period.

    Time frame: Week 24

  4. Double Blind Period: Number of new flares from baseline

    Based on Fibrodysplasia Ossificans Progressiva - Patient RepOrted syMPtoms Tool (FOP-PROMPT).

    Time frame: Week 24

  5. Number of Participants with Treatment Emergent Adverse Events (TEAE)

    Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.

    Time frame: Up to 316 weeks

  6. Open-Label Extension: Occurrence of new HO lesions from Week 24

    HO will be assessed by low dose whole-body computed tomography (WBCT) (excluding the head) from Week 24 to Week 48 compared to baseline to Week 24 in participants randomized to placebo during the DB period.

    Time frame: Week 48

  7. Open-Label Extension: Number of new HO lesions from Week 24

    HO will be assessed by low dose whole-body computed tomography (WBCT) (excluding the head) from Week 24 to Week 48 compared to baseline to Week 24 in participants randomized to placebo during the DB period.

    Time frame: Week 48

  8. Open-Label Extension: Total volume of new HO lesions from Week 24

    HO will be assessed by low dose whole-body computed tomography (WBCT) (excluding the head) from Week 24 to Week 48 compared to baseline to Week 24 in participants randomized to placebo during the DB period.

    Time frame: Week 48

  9. Open-Label Extension: Change in the total volume of all HO lesions from Week 24

    HO will be assessed by low dose whole-body computed tomography (WBCT) (excluding the head) from Week 24 to Week 48 compared to baseline to Week 24 in participants randomized to placebo during the DB period.

    Time frame: Week 48

  10. Open-Label Extension: Number of new flares from Week 24

    Based on Fibrodysplasia Ossificans Progressiva - Patient RepOrted syMPtoms Tool (FOP-PROMPT) from Week 24 to Week 48 compared to baseline to Week 24 in participants randomized to placebo during the DB period.

    Time frame: Week 48

  11. Pharmacokinetics Parameter: Cmax of INCB000928

    Maximum observed concentration.

    Time frame: Baseline, Weeks 12, 24, 48 and 76

  12. Pharmacokinetics Parameter: Tmax of INCB000928

    Time to maximum concentration.

    Time frame: Baseline, Weeks 12, 24, 48 and 76

  13. Pharmacokinetics Parameter: Cmin of INCB000928

    Minimum observed concentration.

    Time frame: Baseline, Weeks 12, 24, 48 and 76

  14. Pharmacokinetics Parameter: AUCt of INCB000928

    Area under the plasma concentration-time curve from time 0 to the last quantifiable measurable plasma concentration

    Time frame: Baseline, Weeks 12, 24, 48 and 76

07

Study locations

11 of 24 sites recruiting
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
    Recruiting
  • Children'S Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Penn Medicine - Perelman Center For Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Italiano de Buenos Aires
    Buenos Aires, CO 1181, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Royal North Shore Hospital
    St Leonards, New South Wales 02065, Australia
    Completed

    Not enrolling at this site — choose another above.

  • Murdoch Children'S Research Institute
    Parkville, Victoria 03052, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Albert Einstein Israelite Hospital
    São Paulo, 05652-900, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Health Network Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro de Estudios Reumatologicos
    Santiago, 7501126, Chile
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Beijing Childrens Hospital Capital Medical University
    Beijing, 100045, China
    Recruiting
  • Tongji Hospital of Tongji University
    Shanghai, 200065, China
    Recruiting
  • Shanghai Childrens Medical Center
    Shanghai, 200127, China
    Recruiting
  • Childrens Hospital of Fudan University
    Shanghai, 201102, China
    Recruiting
  • Ap-Hp Hopital Lariboisiere
    Paris, 75010, France
    Recruiting
  • Hopital Necker-Enfants Malades
    Paris, 75015, France
    Recruiting
  • Uniklinik Koln
    Cologne, 50931, Germany
    Recruiting
  • Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore
    Rome, 00168, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra
    Tlalpan, 14389, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Amsterdam Umc - Vu Medisch Centrum (Vumc)
    Amsterdam, 1081 HV, Netherlands
    Recruiting
  • Starship Childrens Hospital
    Auckland, 01023, New Zealand
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Groote Schuur Hospital Radiation Oncology
    Cape Town, 07925, South Africa
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Seoul National University Hospital
    Seoul, 03080, South Korea
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitario Ramon Y Cajal
    Madrid, 28034, Spain
    Recruiting
  • Royal National Orthopaedic Hospital
    Stanmore, HA7 4LP, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

References and documents

Publications

  • Yang YO, Fang Y, Wang P, Liu X, Getsy J, Rockich K. Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib. Br J Clin Pharmacol. 2026 May;92(5):1339-1351. doi: 10.1002/bcp.70372. Epub 2025 Dec 8. PubMed 41360500 ↗

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for Jul 2027, 62 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2021
First posted
Oct 25, 2021
StartActual
May 5, 2022
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jan 20, 2033
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05090891
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Oct 25, 2021
Start date
May 5, 2022
Primary completion
Jul 30, 2027 (estimated)
Completion
Jan 20, 2033 (estimated)
Last update
Oct 22, 2026

Study contacts

Incyte Corporation Call Center (US)
Contact
medinfo@incyte.com
1.855.463.3463
Incyte Corporation Call Center (ex-US)
Contact
eumedinfo@incyte.com
+800 00027423
Amanda McBride, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zilurgisertib

Start the discussion